STAT

Teva and Mylan to jumpstart production of old malaria drug to fight the novel coronavirus

“People saw these abstracts and it didn’t take long for doctors to write prescriptions and the drugs to go on shortage,” said Erin Fox of University of Utah Health Care.

Two manufacturers of a decades-old malaria drug that some research has suggested may be useful in combating the novel coronavirus announced steps to provide millions of tablets over the next few weeks after the Trump administration singled out the medicine for expedited testing and broader use.

Mylan () and Teva Pharmaceuticals () plan to jumpstart production of hydroxychloroquine, which is also approved for treating lupus or rheumatoid arthritis. The medicine has been prescribed sparingly, mostly to travelers, and was in this month,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks